FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594765993> ?p ?o ?g. }

• W2594765993 abstract "Abstract Objectives: The mobilization chemotherapy should be directed toward the dual objectives of good antilymphoma activity and adequate PBSC mobilization. Previously, we reported the ESHAP plus G-CSF is an effective mobilization regimen in patients with relapsed and high risk NHL. The purpose of this study is to assess the efficacy and feasibility of autologous stem cell collection after mobilization with Rituximab plus ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) combination therapy in B-cell Non-Hodgkin’s lymphoma. Patients and Methods: CD20 + B-cell NHL patients with either high risk, relapsed or refractory patients were eligible for the study. The regimen consisted of: Rituximab 375mg/m2 given on day 1, standard ESHAP therapy (etoposide 40mg/m2 IV/2hr day 2–5, methylprednisolone 500mg/m2 days 2–6, cytarabine 2g/m2 IV/3hr on day 5 and cisplatin 25mg/m2 CIV days 2–5). In all patients, the collection of PBSC was performed during recovery after giving G-CSF (10μ/kg/day) started on day 7. The first harvest was started only if the peripheral blood hematopoietic progenitor cell (HPC) count exceeded 5/μl. Results: Fifty-five mobilization procedures performed on 20 patients with a median of three apheresis (range 2–5) per patient. Median age was 37 years (range 15–65). At the time of PBSC mobilization, Seventeen patients were considered to be responsive (CR, PR and sensitive relapse). Aphereses were started on day 16 (range 13–18). The number of total MNCs (×106/kg) collected was 5.4 (range, 1.4–14.5) and the number of CD34+cells (× 106/kg) was 10.6 (range, 4.9–52.6). The median days of G-CSF usage was 11(range 9–15). Most non-hematologic adverse events were mild and reversible. Nineteen patients (95%) were achieved optimal response, which was defined as ≥ 5 × 106 CD34 cells/kg. In all, sixteen of the patients underwent high-dose chemotherapy. The median time to ANC ≥ 0.5 × 109/L was 10 days (range, 8–17). The median days to platelets ≥ 20 × 109/L was 12 (range, 7–27). Conclusion: Addition of Rituximab to ESHAP chemotherpy does not show any adverse effect in autologous stem cell mobilization and collection. R-ESHAP regimen is effective as a combined mobilization and second-line regimen for patients with pretreated B-cell lymphoma. Figure 1. Days to achieve optimal response Figure 1. Days to achieve optimal response" @default.
• W2594765993 created "2017-03-16" @default.
• W2594765993 creator A5014222628 @default.
• W2594765993 creator A5029347173 @default.
• W2594765993 creator A5037721288 @default.
• W2594765993 creator A5044342301 @default.
• W2594765993 creator A5044958787 @default.
• W2594765993 creator A5056692743 @default.
• W2594765993 creator A5067307453 @default.
• W2594765993 creator A5072307156 @default.
• W2594765993 creator A5073284312 @default.
• W2594765993 creator A5075714089 @default.
• W2594765993 creator A5087021923 @default.
• W2594765993 date "2006-11-16" @default.
• W2594765993 modified "2023-10-16" @default.
• W2594765993 title "Mobilization of Peripheral Blood Stem Cells with Rituximab Plus ESHAP Combination Regimen in B-Cell NHL - Preliminary Results." @default.
• W2594765993 doi "https://doi.org/10.1182/blood.v108.11.5443.5443" @default.
• W2594765993 hasPublicationYear "2006" @default.
• W2594765993 type Work @default.
• W2594765993 sameAs 2594765993 @default.
• W2594765993 citedByCount "0" @default.
• W2594765993 crossrefType "journal-article" @default.
• W2594765993 hasAuthorship W2594765993A5014222628 @default.
• W2594765993 hasAuthorship W2594765993A5029347173 @default.
• W2594765993 hasAuthorship W2594765993A5037721288 @default.
• W2594765993 hasAuthorship W2594765993A5044342301 @default.
• W2594765993 hasAuthorship W2594765993A5044958787 @default.
• W2594765993 hasAuthorship W2594765993A5056692743 @default.
• W2594765993 hasAuthorship W2594765993A5067307453 @default.
• W2594765993 hasAuthorship W2594765993A5072307156 @default.
• W2594765993 hasAuthorship W2594765993A5073284312 @default.
• W2594765993 hasAuthorship W2594765993A5075714089 @default.
• W2594765993 hasAuthorship W2594765993A5087021923 @default.
• W2594765993 hasConcept C126322002 @default.
• W2594765993 hasConcept C129470790 @default.
• W2594765993 hasConcept C13373296 @default.
• W2594765993 hasConcept C141071460 @default.
• W2594765993 hasConcept C143998085 @default.
• W2594765993 hasConcept C170493617 @default.
• W2594765993 hasConcept C2776694085 @default.
• W2594765993 hasConcept C2778041864 @default.
• W2594765993 hasConcept C2778119113 @default.
• W2594765993 hasConcept C2778336483 @default.
• W2594765993 hasConcept C2778828106 @default.
• W2594765993 hasConcept C2779338263 @default.
• W2594765993 hasConcept C2780372218 @default.
• W2594765993 hasConcept C2780653079 @default.
• W2594765993 hasConcept C2781413609 @default.
• W2594765993 hasConcept C71924100 @default.
• W2594765993 hasConcept C90924648 @default.
• W2594765993 hasConceptScore W2594765993C126322002 @default.
• W2594765993 hasConceptScore W2594765993C129470790 @default.
• W2594765993 hasConceptScore W2594765993C13373296 @default.
• W2594765993 hasConceptScore W2594765993C141071460 @default.
• W2594765993 hasConceptScore W2594765993C143998085 @default.
• W2594765993 hasConceptScore W2594765993C170493617 @default.
• W2594765993 hasConceptScore W2594765993C2776694085 @default.
• W2594765993 hasConceptScore W2594765993C2778041864 @default.
• W2594765993 hasConceptScore W2594765993C2778119113 @default.
• W2594765993 hasConceptScore W2594765993C2778336483 @default.
• W2594765993 hasConceptScore W2594765993C2778828106 @default.
• W2594765993 hasConceptScore W2594765993C2779338263 @default.
• W2594765993 hasConceptScore W2594765993C2780372218 @default.
• W2594765993 hasConceptScore W2594765993C2780653079 @default.
• W2594765993 hasConceptScore W2594765993C2781413609 @default.
• W2594765993 hasConceptScore W2594765993C71924100 @default.
• W2594765993 hasConceptScore W2594765993C90924648 @default.
• W2594765993 hasLocation W25947659931 @default.
• W2594765993 hasOpenAccess W2594765993 @default.
• W2594765993 hasPrimaryLocation W25947659931 @default.
• W2594765993 hasRelatedWork W123479973 @default.
• W2594765993 hasRelatedWork W1509346046 @default.
• W2594765993 hasRelatedWork W2054657079 @default.
• W2594765993 hasRelatedWork W2247855196 @default.
• W2594765993 hasRelatedWork W2592110561 @default.
• W2594765993 hasRelatedWork W2626793247 @default.
• W2594765993 hasRelatedWork W3029503939 @default.
• W2594765993 hasRelatedWork W3043781363 @default.
• W2594765993 hasRelatedWork W4205443186 @default.
• W2594765993 hasRelatedWork W4351535 @default.
• W2594765993 isParatext "false" @default.
• W2594765993 isRetracted "false" @default.
• W2594765993 magId "2594765993" @default.
• W2594765993 workType "article" @default.